This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Aquestive Therapeutics Faces Class...
Business class action lawsuit

Aquestive Therapeutics Faces Class Action Lawsuit

Analysis based on 16 articles · First reported Jan 29, 2026 · Last updated Mar 12, 2026

Sentiment
-20
Attention
2
Articles
16
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of Aquestive Therapeutics facing a class action lawsuit and the indefinite delay in the approval of its drug Aquestive Therapeutics===Anaphylm. This has caused a significant drop in Aquestive Therapeutics' stock price, signaling investor concern.

Pharmaceuticals Legal Services
Event Summary

A class action lawsuit has been filed against Aquestive Therapeutics by Pomerantz LLP, alleging securities fraud and unlawful business practices. This legal action follows an announcement from Aquestive Therapeutics regarding a letter from the United States===Food and Drug Administration, which identified deficiencies in the New Drug Application for its sublingual film, Aquestive Therapeutics===Anaphylm. The FDA's letter effectively delayed the approval of Aquestive Therapeutics===Anaphylm indefinitely. Consequently, Aquestive Therapeutics' stock price fell significantly by 37.04% on January 9, 2026. Investors who purchased Aquestive Therapeutics securities during the Class Period have until May 4, 2026, to seek appointment as Lead Plaintiff.

Key Actions
100 Pomerantz LLP filed class action lawsuit Aquestive Therapeutics
90 Aquestive Therapeutics stock price fell
80 United States===Food and Drug Administration identified deficiencies in NDA Aquestive Therapeutics
Entities Involved
stock
Aquestive Therapeutics
Aquestive Therapeutics is facing a class action lawsuit due to alleged securities fraud and unlawful business practices. This has led to a significant drop in its stock price and a delay in the approval of its drug Aquestive Therapeutics===Anaphylm.
Importance 100 Sentiment -70
priv
Pomerantz LLP
Pomerantz LLP has filed a class action lawsuit against Aquestive Therapeutics, representing investors who purchased Aquestive securities. The firm specializes in corporate, securities, and antitrust class litigation.
Importance 60 Sentiment 20
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration identified deficiencies in Aquestive Therapeutics' New Drug Application for Aquestive Therapeutics===Anaphylm, precluding labeling discussions and effectively delaying its approval indefinitely.
Importance 50 Sentiment 0
subs
Aquestive Therapeutics===Anaphylm
Aquestive Therapeutics===Anaphylm, Aquestive Therapeutics' sublingual film, has had its approval delayed indefinitely by the United States===Food and Drug Administration due to identified deficiencies in its New Drug Application.
Importance 40 Sentiment -50
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.